New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
09:25 EDTSNTI, SNTI, SRNE, SRNE, SPEX, SPEX, CDXC, CDXC, CBMX, CBMX, SSET, SSET, OPK, OPK, CGIX, CGIXRedChip Companies to hold a virtual conference
RedChip Emerging Growth Showcase is being held on January 22-23 with webcasted presentations to begin on January 23 at 9:30 am. Webcast Link
News For OPK;CGIX;SNTI;SRNE;SPEX;CDXC;CBMX;SSET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
08:12 EDTCBMXCombiMatrix executes final settlement ending litigation
Subscribe for More Information
April 23, 2015
07:07 EDTCGIXRedChip to hold a virtual conference
Subscribe for More Information
April 22, 2015
07:16 EDTOPKOPKO Health score test shows positive prostate cancer risk identification result
Opko Health (OPK) announced the publication of a study showing that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore Test accurately identifies risk for aggressive prostate cancer prior to prostate biopsy. The Prostate Testing for Cancer and Treatment study is a prospective randomized controlled trial conducted in the U.K. for the purpose of evaluating the cost effectiveness of conventional treatments in PSA-detected, clinically localized prostate cancer. The study showed that the four kallikrein panel enhanced aggressive prostate cancer detection compared with PSA and age alone.
07:16 EDTCGIXRedChip to hold a virtual conference
Subscribe for More Information
April 21, 2015
10:59 EDTOPKOPKO Health announces publication of ProtecT study
OPKO Health announced the online publication of a study entitled “Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study” in the Journal of the National Cancer Institute. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore Test accurately identifies risk for aggressive prostate cancer prior to prostate biopsy. The Prostate Testing for Cancer and Treatment, or ProtecT, study is a prospective randomized controlled trial conducted in the United Kingdom for the purpose of evaluating the cost effectiveness of conventional treatments in PSA-detected, clinically localized prostate cancer. Of the 82,428 men recruited for the trial, a total of 6129 men with elevated PSA who underwent prostate biopsy and provided an adequate blood sample were tested for the four kallikreins and their 4Kscore result was determined. The study showed that the four kallikrein panel enhanced aggressive prostate cancer detection compared with PSA and age alone. The area under the curve for the 4K model was 0.820 while the PSA model was 0.738 for high-grade cancer.
April 19, 2015
15:38 EDTSRNESorrento Therapeutics announces 3 preclinical poster presentations on Cynviloq
Subscribe for More Information
April 16, 2015
09:18 EDTCGIXOn The Fly: Pre-market Movers
Subscribe for More Information
08:04 EDTCGIXCancer Genetics receives NY State licensure for FHACT cervical cancer test
Subscribe for More Information
April 14, 2015
11:35 EDTCDXCChromaDex management to meet with Roth Capital
Meeting to be held in Chicago on April 20 hosted by Roth Capital.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use